

Quintiles to advise Ascendancy on pharma deals in China

30 July 2013 | News | By BioSpectrum Bureau



Singapore: San Francisco-based Ascendancy Healthcare has tied up with Quintiles to get help from the contract research giant in order to leverage on China's growing pharma market.

Quintiles will be advising Ascendancy on which compounds to license in a deal that will last 2.5 years. Quintiles will lend clinical research services and market access assistance in China and other Asian markets.

"Ascendancy intends to buy the China rights to late-stage therapies worldwide, and Quintiles' expertise will help it execute the plan. We are in active discussions with innovative pharma and life sciences firms and expect to announce our first product licensing deal in the second half of this year," said Ms Sandy Zweifach, CEO, Ascendancy.